| P2093 | author name string | S R Shah | |
| | U Verma | |
| | E Marley | |
| | J E Dowell | |
| | J Liticker | |
| | S M Gressett Ussery | |
| | Y Arriaga | |
| P2860 | cites work | Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer | Q46502913 |
| | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. | Q46755325 |
| | A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. | Q51486727 |
| | Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | The biology of VEGF and its receptors | Q27860704 |
| | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| | Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma | Q33382596 |
| | Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy | Q34354300 |
| | Diabetic nephropathy: diagnosis, prevention, and treatment | Q34379284 |
| | Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial | Q34555503 |
| | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 |
| | Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 |
| | The role of vascular endothelial growth factor (VEGF) in renal pathophysiology | Q35776377 |
| | Timed urine collections are not needed to measure urine protein excretion in clinical practice | Q36353288 |
| | Antihypertensive therapy in the presence of proteinuria | Q36690664 |
| | Nephrotic syndrome after bevacizumab: case report and literature review | Q36721460 |
| | Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer | Q37219981 |
| | Intricacies of bevacizumab-induced toxicities and their management | Q37406599 |
| P433 | issue | 4 | |
| P921 | main subject | bevacizumab | Q413299 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 960-965 | |
| P577 | publication date | 2012-11-21 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension | |
| P478 | volume | 24 | |